Sonax Xtreme Clear View 1:100
Sonax Xtreme Clear View 1:100
Sonax Xtreme Clear View 1:100
GHS07
55.1.0
Page 2/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 1)
P337+P313 If eye irritation persists: Get medical advice/attention.
P501 Dispose of contents/container in accordance with local/regional/national/international
regulations.
Labelling of packages where the contents do not exceed 125 ml
Marking container <125 ml deviates. Reduced labeling according article 29 and annex I, no. 1.5 GB CLP-
regulation is used.
2.3 Other hazards
Results of PBT and vPvB assessment
PBT:
According to information provided in the supply chain, the mix contains less than 0.1% of any substances
classified as PBT
vPvB:
According to information provided in the supply chain, the mix contains less than 0.1% of any substances
classified as vPvB.
Determination of endocrine-disrupting properties
The substance/mixture does not contain components considered to have endocrine disrupting properties
according to UK REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission
Regulation (EU) 2018/605 at levels of 0.1% or higher.
55.1.0
Page 3/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 2)
5.3 Advice for firefighters
Protective equipment:
The normal measures for firefighting are to be taken.
Do not enter the hazardous area without a self-contained breathing apparatus.
See Section 8 for information on personal protection equipment.
55.1.0
Page 4/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 3)
DNELs
CAS: 107-98-2 1-Methoxy-2-propanol
Oral DNEL 3.3 mg/kg (consumer) (long-term / systemic effects)
Dermal DNEL 18.1 mg/kg (consumer) (long-term / systemic effects)
50.6 mg/kg (worker) (long-term / systemic effects)
Inhalative DNEL 43.9 mg/m³ (consumer) (long-term / systemic effects)
553.5 mg/m³ (worker) (short-term / local effects)
DNEL 369 mg/m³ (worker) (long-term / systemic effects)
PNECs
CAS: 107-98-2 1-Methoxy-2-propanol
PNEC 100 mg/l (STP)
100 mg/l (water (intermittent release))
10 mg/l (water (fresh water))
1 mg/l (water (sea water))
PNEC 2.47 mg/kg (gro)
41.6 mg/kg (sediment (fresh water))
4.17 mg/kg (sediment (sea water))
Additional information: The lists valid during the making were used as basis.
8.2 Exposure controls
Individual protection measures, such as personal protective equipment
General protective and hygienic measures:
The usual precautionary measures are to be adhered to when handling chemicals.
Wash hands before breaks and at the end of work.
Keep away from foodstuffs, beverages and feed.
Respiratory protection:
Not required in normal cases
Ensure good ventilation/exhaustion at the workplace.
Hand protection
Protective gloves
The glove material has to be impermeable and resistant to the product/ the substance/ the preparation.
Material of gloves
Nitrile rubber, NBR
Recommended thickness of the material: ≥ 0.4 mm
[EN 374]
Penetration time of glove material
Value for the permeation: Level 5 (240 - <480min)
The determined penetration times according to EN 16523-1:2015 are not performed under practical
conditions. Therefore a maximum wearing time, which corresponds to 50% of the penetration time, is
recommended.
Eye/face protection
Safety glasses
[EN 166]
55.1.0
Page 5/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 4)
55.1.0
Page 6/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 5)
LD/LC50 values relevant for classification:
CAS: 107-98-2 1-Methoxy-2-propanol
Oral LD50 4,016 mg/kg (rat)
Dermal LD50 >2,000 mg/kg (rat)
Inhalative LC0 / 6h >7,000 ppm (rat)
Skin corrosion/irritation Causes skin irritation.
Serious eye damage/irritation Causes serious eye irritation.
Respiratory or skin sensitisation Based on available data, the classification criteria are not met.
Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Reproductive toxicity Based on available data, the classification criteria are not met.
STOT-single exposure Based on available data, the classification criteria are not met.
STOT-repeated exposure Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.
11.2 Information on other hazards
Endocrine disrupting properties
According to the current state of scientific knowledge, there is no data for the product regarding endocrine
disrupting properties with health effects.
None of the ingredients is listed.
55.1.0
Page 7/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 6)
12.7 Other adverse effects
Additional ecological information:
General notes:
Do not allow undiluted product or large quantities of it to reach ground water, water course or sewage system.
55.1.0
Page 8/8
Safety data sheet
according to 1907/2006/EC, Article 31
Printing date 09.01.2023 Version: 8.00 (replaces version 7.00) Revision: 24.09.2021
(Contd. of page 7)
National regulations:
Information about limitation of use:
Employment restrictions concerning pregnant and lactating women must be observed.
Employment restrictions concerning juveniles must be observed.
15.2 Chemical safety assessment: A Chemical Safety Assessment has not been carried out.
55.1.0